Pathos Signs Strategic Agreements with AstraZeneca and Tempus to Develop the Largest Multimodal Foundation Model in Oncology

CHICAGO, April 23, 2025 — Pathos AI, Inc.(www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Tempus AI, Inc. (NASDAQ: TEM), in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Pathos will use Tempus’ de-identified oncology data to